The Department does not hold data on the number of people in England with a formal clinical diagnosis of mixed anxiety and depressive disorder recorded in National Health Service primary care records.

The Quality and Outcomes Framework publication shows the prevalence of depression more broadly, with the depression disease register capturing all patients with an unresolved diagnosis of depression since 1 April 2006. However, it does not break this down by the number of patients with a specific type of diagnosis. The Quality and Outcomes Framework publication is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2023-24/data-quality-annex

The most recent Adult Psychiatric Morbidity Survey, for 2023/24, reported that one in five adults have a common mental health condition, which comprise of different types of depression and anxiety disorders.

The Department has commissioned an independent review into the prevalence, trends, and inequalities associated with mental health conditions, attention deficit hyperactivity disorder, and autism in children, young people, and adults. An interim report was published in March, with a final report expected in the summer. The interim report is available at the following link:

https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-interim-report

The data for this question is unavailable. NHS England does not report waiting times data for specific conditions unless there is an existing waiting times standard, for example Children and Young People eating disorders or Early Intervention in Psychosis.

There are no plans at present to increase the provision of Transcranial Magnetic Stimulation for depression based on current National Institute for Health and Care Excellence guidance. Integrated care boards are responsible for providing health and care services to meet the needs of their local populations.

There are no plans at present to increase the provision of Transcranial Magnetic Stimulation for depression based on current National Institute for Health and Care Excellence guidance. Integrated care boards are responsible for providing health and care services to meet the needs of their local populations.

The Department has no plans to ask the National Institute for Health and Care Excellence (NICE) to conduct a review of the NICE guideline on the treatment and management of depression, reference code NG222.

NICE is an independent body and is responsible for taking decisions on whether its guidelines should be updated in light of new evidence and changes in clinical practice. NICE operates an active surveillance programme and when new evidence emerges, it proactively considers whether existing guidance should be reviewed and, if appropriate, updated. Decisions as to whether NICE will create new, or update existing, guidance are overseen by an integrated, cross-organisational prioritisation board. NICE has no current plans to review intravenous racemic ketamine in the context of the depression guideline.

The NHS Business Services Authority (NHS BSA) does not collect data on the clinical indication of a prescription. Given this, it is not possible to deduce which prescriptions were prescribed for depression. Many drugs have multiple uses, for example, some drugs that are classified as antidepressants can be issued to treat migraine, chronic pain, myalgic encephalomyelitis, and a range of other conditions.

The NHS BSA publishes statistics on mental health, which includes British National Formulary section 4.3 ‘Antidepressants drugs’, prescribed in England that are then dispensed in the community in England, Scotland, Wales, the Isle of Man, or the Channel Islands.

The following table shows the number of ‘unique patients’ in the latest quarterly statistics July-September 2025, aged 29 years old and under that were prescribed and dispensed antidepressants:

Source: Medicines Used in Mental Health – England, published by NHS England, available at the following link:
https://www.nhsbsa.nhs.uk/statistical-collections/medicines-used-mental-health-england

The requested information on Motability is not part of our routine statistical releases.

The requested information on Motability is not part of our routine statistical releases.

At the end of July 2025 (latest available data), 593,700 PIP claimants had an active contract with the Motability Scheme.

The number of PIP claimants who had an active contract with the Motability Scheme broken down by condition groups over the past 5 years is provided in the table below.

Table 1: PIP claimants with an active Motability Scheme contract by condition over the past 5 years

The Department does not hold Motability data in its analytical datasets for DLA. Obtaining these data from other sources would involve disproportionate costs.

Notes:

- The figures provided are for PIP claimants in England and Wales only.

- The figures include both claims made under Normal Rules and those made under Special Rules for End of Life.

- The claimants’ primary conditions were used to categorise them in the provided table. Many claimants have two or more health conditions, and it is not necessarily the case that the listed primary condition is that which gives rise to the functional limitation(s) behind the award of the enhanced mobility component of PIP.

- The figures have been provided in calendar years, containing data from January 2020 to July 2025.

- The calendar year 2025 only contains data to July 2025, therefore volumes may be smaller than what would appear within a full calendar year. Data beyond this point is currently unavailable centrally for analysis.

- Values in the table show any PIP claimant with an active Motability Scheme contract on the PIP caseload at some point within that calendar year.

- The “of which any depressive disorder” category is made up of 4 primary conditions:

o Anxiety and depressive disorders – mixed

o Bipolar affective disorder

o Depressive disorder

o Mood disorders – Others / type not known

- Values have been rounded to the nearest 100.

The Department delivers dementia research via the National Institute for Health and Care Research (NIHR). Recently completed NIHR-funded research has found that depression across the life course is associated with an increased risk of dementia, but that this is strongest in mid to late life. Further research is needed to determine whether the strength of this association is due to depression as a risk factor for dementia or the early presentation of neurodegenerative processes.

The NIHR is funding the £2.9 million ENHANCE programme, which will develop an app intervention to address risk factors for dementia, including depression, and will test it to see the effects on cognition, risk, quality of life, and affordability. In the long-term, the research will examine health records to see if the app intervention has reduced rates of dementia. NIHR-funded research is also seeking to understand whether compassion focused therapy is an acceptable intervention for people with dementia and depression or anxiety.

The NIHR continues to welcome funding applications for research into any aspect of human health and care, including dementia. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on dementia to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research that can be funded.

This information is not held in the format requested. NHS England publishes data on the average waiting time for patients to start treatment with NHS Talking Therapies services, but the condition with which a person may be presenting is not recorded.

The table below shows the number of claimants aged 16-24 receiving the different award types for both daily living and mobility components of Personal Independence Payment (PIP), and for those aged 16-24 whose primary condition was Anxiety or Depression.

Table 1: Number of claimants aged 16-24 years receiving PIP in England and Wales by award rate for Daily Living and Mobility, split by all medical conditions and Anxiety and Depression only.

Notes:

• Data source: Stat-Xplore.
• Data is for England and Wales only.
• Data is for March of each financial year apart from the 2024_25 financial year which is for October 2024, the latest published data.
• A&D refers to Anxiety and Depression.
• In line with previously published analysis, to calculate cases with primary condition Anxiety and Depression we included the Stat-Xplore categories: ‘Stress reactions’, ‘Anxiety disorders’, ‘Obsessive compulsive disorder’, ‘Mixed anxiety and depressive disorders’ and ‘Mood disorders’.
• Data has been rounded to the nearest 100.
• DL refers to Daily Living component of PIP.
• Mob refers to the Mobility component of PIP.
• Enh refers to the Enhanced award rate which is the highest Daily Living or Mobility award.
• Std refers to the Standard award rate which is the lowest Daily Living or Mobility award.
• Nil refers to when a claimant does not receive that award for Daily Living or Mobility award.

A number of anti-depressant products have been licenced by the Medicines and Healthcare products Regulatory Agency (MHRA). These medicines are prescription only, and must only be prescribed by a healthcare professional.

Each individual product is assessed for its efficacy and safety in a specific indication prior to the issuing of a marketing authorisation. Only when the benefit-risk analyses have been shown to be positive in relation to quality, safety, and efficacy, will a product obtain an approval.

The Product Information for each product will include not only the details of the indication, but will also include posology, or the dose recommendations, contra-indications, a list of known side-effects, and a reference to the Yellow Card Scheme, for reporting new side-effects. Safety is regularly monitored in order to detect any safety signal not recorded during the clinical trials and once the drug is available to a wider population.

Details of products approved by the MHRA, including therapeutic indications, can be found by searching ‘antidepressant’ on the MHRA website, which is available in an online only format.

The effectiveness of the product, which is measured post-authorisation, is considered by the National Institute for Health and Care Excellence (NICE), and other learned bodies, for the development of clinical guidance.

It should be noted that non-pharmacological alternatives may also be recommended to a patient, however this a decision for the healthcare professional.

The NICE is the independent body responsible for translating evidence into authoritative guidance and best practice for the health and care system. NICE guidelines provide recommendations in terms of both the effectiveness and cost-effectiveness of interventions and services, and National Health Service organisations are expected to take them fully into account in designing services that meet the needs of their local populations.

The NICE has published guidance on the treatment and management of depression in adults which provides recommendations on the use of antidepressants and non-drug treatments for depression.

The Department, through the National Institute for Health and Care Research (NIHR), funds a range of research to improve the health outcomes for people with depression. This includes research into the clinical and cost-effectiveness of non-drug related approaches to treatment of the condition.

For example, the NIHR has funded research that demonstrated that mindfulness cognitive therapy delivered by a practitioner is an effective alternative to, and more cost effective than, cognitive behavioural therapy for adults with mild to moderate depression, providing alternative treatment options.

In addition, the NIHR is currently funding a £1.5 million randomised controlled trial to test the clinical and cost effectiveness of artificial intelligence (AI) driven care for depression symptoms in comparison to current practice, stepped care, which starts with less intensive treatments, followed by more intensive treatments for patients for whom the initial treatment fails. AI driven stratified care, which involves targeting treatment towards groups of patients based on key characteristics, could improve the evidence on how to decide which non-drug related approaches, like psychological therapy, may be most effective for each individual, and help to plan and deliver more effective clinical services.

The NIHR welcomes funding applications for research into any aspect of mental health, including non-drug related approaches to treating depression. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.

The Department does not hold this information centrally.

No such estimates have been made, as the information is not held in the format requested. Veterans may be treated in several National Health Service settings, including primary care, community mental health, and specialist services. Veterans are not systematically identified in all settings, and data is not systematically collated and aggregated across settings.

On Employment Support Allowance and out of work Universal Credit, the information requested is not readily available due to how the medical condition is recorded so to collate and provide it would incur disproportionate cost. However, Monthly statistics on the outcomes of Employment and Support Allowance work capability assessments are available by primary high-level medical condition on Stat-Xplore. The latest statistics are available by date of decision from November 2008 to September 2023, or date of claim start from October 2008 to June 2023. Statistics on the outcomes of Universal Credit work capability assessments (UC WCA) are available by high-level medical condition for the period from January 2022 to November 2023 in Table 7 of the latest UC WCA data tables.

On Disability Living Allowance (DLA), the information requested is in the attached document.

Points to note:

• Figures are only readily available on a quarterly basis, to provide the requested information per month would incur a disproportionate cost.
• Figures cover both DLA Adult and DLA Child on the caseload at a given month.
• Figures are rounded to the nearest 1,000.
• Figures are for England and Wales only.
• Figures follow Personal Independence Payment’s (PIP) definition of main disabling conditions, and therefore, can be compared to PIP figures.

The latest available data on Personal Independence Payment claims can be found at https://stat-xplore.dwp.gov.uk/. The volume of PIP claimants with certain conditions can be found in the ‘PIP Cases with Entitlement’ dataset by going to ‘Disability’ and selecting the relevant conditions. To show the data since April 2013, select all months and then ‘Add to Column/Row’.

The data is based on primary disabling condition as recorded on the PIP computer systems. Claimants may often have multiple disabling conditions upon which the decision is based but only the primary condition is shown in these statistics. PIP was first introduced in April 2013, so there is no data available before this point.

Guidance on how to use Stat-Xplore can be found here. An account is not required to use Stat- Xplore, the ‘Guest Login’ feature gives instant access to the main functions.